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Background: The nature of the relationship between Helicobacter pylori and reflux esophagitis (RE) is not fully
understood. In addition, the effect of H. pylori eradication on RE and gastroesophageal reflux disease (GERD) is
unclear. This study was designed to investigate the relationship between H. pylori infection and the grade of GERD
in patients with reflux symptoms.
Methods: Between January 2010 and July 2013, 184 consecutive patients with daily reflux symptoms for at least
one year were evaluated at the ambulatory for functional esophageal disease, Tor Vergata University Hospital,
Rome, Italy. All patients underwent a pretreatment evaluation, which included anamnesis, clinical examination,
Esophagogastroduodenoscopy (EGDS) with biopsy, esophageal manometry and 24-hour pH-metry. All statistical
elaborations were obtained using Statigraphies 5 plus for Window XP.
Results: There was no statistical difference regarding Lower Esophageal Sphincter (LES) pressure between patients
who were H. pylori-positive and H. Pylori-negative (19.2 ± 9.5 (range: 3.7 to 46.2) and 19.7 ± 11.0 (range: 2.6 to 61),
respectively). Further, no significant difference was evidenced in esophageal wave length (mean value: 3.1 seconds
in H. pylori-negative patients versus 3.2 seconds in H. pylori-positive patients) or in esophageal wave height (mean
value: 72.2 ± 39.3 in H. pylori-negative patients versus 67.7 ± 28.4 in H. pylori-positive patients). We observed that
hiatal hernia (P = 0.01), LES opening (P = 0.05), esophageal wave length (P = 0.01) and pathological reflux number
(P = 0.05) were significantly related to the presence of esophagitis. However, H. pylori infection was not significantly
related to the presence of reflux esophagitis.
Conclusions: Our clinical, endoscopic, manometric and pH-metric data shows no significant role of H. pylori
infection in the development of GERD or in the pathogenesis of reflux esophagitis. However, current data do not
provide sufficient evidence to define this relationship and further prospective large studies are needed.
Keywords: Helicobacter pylori, RE, GERD, Esophageal manometry, Endoscopic procedureBackground
Helicobacter pylori (HP) infection plays a major role in
the pathogenesis of peptic ulcer disease, chronic gastri-
tis, gastric mucosa-associated lymphoid tissue lymph-
oma (MALToma) and the development of gastric
cancer. However, its role in reflux-induced esophageal* Correspondence: grande@uniroma2.it
1Department of Experimental Science and Surgery, Policlinico “Tor Vergata”,
Viale Oxford, 81, 00133 Rome, Italy
2Department of Surgery, University Hospital Tor Vergata, Viale Oxford, 81,
00133 Rome, Italy
© 2014 Grande et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.injury (reflux esophagitis (RE)) and gastroesophageal re-
flux disease without esophagitis (GERD) is not fully
understood. In addition, the effect of H. pylori eradica-
tion on RE or GERD is unclear. Several reports have
shown an association of H. pylori eradication with the
development of RE or GERD symptoms [1-3]. However,
contradictory results have been reported, and sometimes
a beneficial effect of H. pylori eradication on GERD has
been observed [4-6].
Despite the results of these studies, it is conceivable
that H. pylori could contribute to esophagitis in GERD. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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1) H. pylori infection might cause a predisposition to
GERD by increasing gastric acid secretion, 2) H. pylori
might cause esophageal damage by directly infecting the
gastric-type columnar epithelium that can line the distal
esophagus normally or as part of Barrett's esophagus or 3)
H. pylori might cause esophageal damage indirectly
through the action of noxious substances that are secreted
by the organism into the refluxed gastric juice [7].
Colonization of gastric mucosa by H. pylori may result
in hypochlorhydria in patients with diffuse gastritis and
gastric atrophy and who seem to be at less risk of develop-
ing GERD [8]. Therefore, association between H. pylori in-
fection and development of either hypochlorhydria or
hyperacid secretion depends on the inflammatory re-
sponse of the gastric mucosa. Thus, the effect of H. pylori
infection on the development of GERD is contradictory
and is an intricate relationship [8]. This study was de-
signed to investigate the relationship between H. pylori in-
fection and the grade of GERD in patients with reflux
symptoms.
Methods
Between January 2010 and July 2013, 184 consecutive
patients with daily reflux symptoms for at least one year
were evaluated at the ambulatory for functional esopha-
geal disease, Tor Vergata University Hospital, Rome,
Italy, and were included in this prospective study. The
study had been approved by the Institutional Committee
of the Tor Vergata University of Rome.
We classified the symptoms of the patients as did Patti
et al. [9]; a patient-estimated scale ranging from 0 (no
symptom) to 4 (disabling symptom). Swallowing status
was graded as follows: excellent (no dysphagia), good
(occasional dysphagia), fair (frequent dysphagia requiring
dietary adjustments) or poor (severe dysphagia prevent-
ing the ingestion of solid food).
Exclusion criteria were: previous therapy to eradicate
H. pylori, concomitant assumption of aspirin and non-
steroidal antiinflammatory drugs or previous surgical
procedures on the digestive tract. All patients underwent
pretreatment evaluation, which included anamnesis,
clinical examination, EGDS with biopsy, esophageal
manometry and 24 hours pH-metry. Symptoms (heart-
burn, pain and regurgitation) were assessed by patients'
visits. Outpatient manometry and pH studies were per-
formed using a conventional protocol.
The study has not evaluated the degree of GERD as
we are only interested in the correlation between RE
and GERD. Kusano et al. [10] have shown that the
Frequency Scale for Symptoms of GERD (FSSG) is
useful only to evaluate therapeutic efficacy in GERD
patients during the follow-up period without repeated
endoscopy.Esophageal manometry
All subjects presented for a manometry after fasting for
a minimum of eight hours. Medications known to inhibit
or affect esophageal motility (nitrates, metoclopramide
hydrochloride or calcium channel-blocking agents) were
discontinued five days before manometry or 24-hour pH
monitoring. A six-way perfusion water catheter (three ra-
dial and three spaced at 1-cm intervals) was used for all
studies. The catheter was calibrated from 0 to 50 mmHg
immediately before use (Medtronic Polygram Net™ version
4.01. Tonsbakken, Denmark).
An esophageal manometry was performed in order to de-
fine the position, extension, pressure of Lower Esophageal
Sphincter (LES) (resting pressure and relaxation), amp-
litude, duration and velocity of esophageal peristaltic.
Esophageal motility and gastroesophageal junction co-
ordination were evaluated using 5 ml of room
temperature water in a sequence of 10 swallows. Double
swallows and swallows including pressure artefacts as-
sociated with coughing or belching were not counted in
the 10 swallows.
24-hour esophageal pH monitoring
During the study the patients consumed an unrestricted
diet and took no medications that could interfere with
the results. Esophageal pH monitoring was conducted
using an antimony pH catheter with external or internal
reference (AccuView pH, Sierra Scientific Instruments.
Yoqneam, Israel). The sensor was positioned 5 cm above
the LES. Continuous pH recording was performed for
24 hours.
The DeMeester score [11] was used to calculate the
following distal pH variables: percentage of total time
that pH was less than 4, percentage of supine time that
pH was less than 4, percentage of upright time that pH
was less than 4, longest reflux event, number of reflux
events longer than five minutes, and number of reflux
episodes in 24 hours. A DeMeester score of greater than
14.72 was considered abnormal.
In patients with an abnormal reflux score (reference
reflux score: 14.7), tracings were analyzed to distinguish
between false reflux (due to stasis and fermentation) and
true reflux [8]. When the clinical picture was ambiguous
(a patient with good response to Proton Pump Inhibitors
(PPIs) and esophagitis, or a normal but borderline reflux
score), the pH monitoring study was repeated after three
weeks.
Endoscopic procedure
All study subjects underwent upper gastrointestinal endo-
scopic examinations. The endoscopic findings of RE in the
lower esophagus were classified according to the Savary-
Miller classification [12], based on the longest length of
the mucosal break and confluence of erosions. Esophagitis
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esophagitis was defined as the presence of single or iso-
lated erosion on one mucosal fold; grade 2, non-
circumferential erosions on more than one mucosal fold
with or without confluence; grade 3, circumferential ero-
sions that may be confluent; grade 4, ulcer, stricture, or
esophageal shortening and Barrett's epithelium.
A hiatal hernia was endoscopically defined as a
distance from the esophagogastric junction to the dia-
phragmatic impingement of more than 1 cm. The eso-
phagogastric junction was defined as the proximal
margin of the gastric mucosal fold [3]. Barrett's esopha-
gus has been defined as the presence of squamo-
columnar metaplasia localized at least 3 cm above the
esophagus-gastric junction; two to three samples of the
lower esophagus (last 3 cm) were obtained [12]. An
endoscopic biopsy both of the gastric body and the an-
trum was performed in order to diagnose H. pylori infec-
tion and to obtain histological evaluation of the mucosa.
H. pylori infection was diagnosed by the color-coded bi-
opsy test (CCBT); we did not choose the stool antigen
test (SAT) because CCBT is more feasible, faster to per-
form and executable at the time of the endoscopic pro-
cedure. The specimens were preserved in formaldehyde
solution (10%) for histopathologic evaluation.
Statistical analysis
All statistical elaborations were obtained by using Statigra-
phies 5 plus for Window XP (Statsoft; Tulsa, Oklahoma,
United States). Results are expressed as mean values and
standard deviation (SD). Quantitative variables between
the two groups (H. pylori-positive and H. pylori-negative
patients) were compared using the Student's t-test; quali-
tative parameters were compared between the two groups
using chi-squared test. Results were considered statistically
significant at P <0.05.
Results
The present study included 184 patients (73 males and
111 females) with a mean age of 51.5 ± 15.2 years (range:
23 to 89). The baseline characteristics of the two groups
are shown in Table 1.
All patients suffered from daily reflux symptoms for at
least one year, there was no statistical difference regard-
ing the severity of symptoms and symptoms score as
given by the patients between the two groups (Table 2).Table 1 Demographics characteristics of the 184 patients acc
Demographic variables H. pylori-negative patients, n (%)
Number of patients 99 (53.8)
Men 41 (41.4)
Women 58 (58.6)
Age range, years (median) 24 to 74 (48.87)H. pylori infection was diagnosed in 85 patients
(46.2%; 32 males and 53 females), while 99 patients
(53.8%; 41 males and 58 females) were H. pylori-nega-
tive. Patients with and without H. pylori infection were
statistically compared. There were no significant differ-
ences between the two groups regarding age, gender and
presentation of symptoms. Hiatal hernia was found in
122 out of 184 patients (66.3%); 31 of which were H.
pylori-positive (25.4%) and 91 were H. pylori-negative
(74.6%), this data was statistically significant (P <0.0001).
Out of these 122 patients with hiatal hernia, 40 (32.8%)
suffered from RE, and in this group H. pylori-infection
was diagnosed in 10 patients (25%), therefore in 82 pa-
tients (67.2%) with GERD and no RE, H. pylori-infec-
tion was present in 21 cases (25.6%). The incidence of
hiatal hernia between the group with RE (40 patients)
and the group without RE (82 patients) was significant
(P <0.0001).
According to the Savary-Miller classification [9],
132 patients (71.7%) were graded 0 and had GERD
only, and in 52 out of 184 patients (28.3%) reflux
esophagitis was evidenced, of which 18 patients were
graded 1 to 3 (four H. pylori-positive patients and 14
H. pylori-negative) and 34 patients were graded
4 (11H. pylori-positive patients and 23H. pylori-
negative); two of these cases were found to have
Barrett’s esophagus, and both were H. pylori-negative.
Impairment of esophageal motility and presence of
waves dropped and not forwarded was detected at
manometry in 140 patients out of 184 (76%). H. pylori was
present in 33 of these (23.6%), while 107 were H. pylori-
negative (76.4%).
There was no statistical difference regarding LES pres-
sure between patients who were H. pylori-positive and
H. pylori-negative (19.2 ± 9.5 (range: 3.7 to 46.2) and
19.7 ± 11.0 (range: 2.6 to 61), respectively). Further,
significant difference was not evidenced in either
esophageal wave length (mean value: 3.1 seconds in H.
pylori-negative patients versus 3.2 seconds in H. pylori-
positive) nor in esophageal wave height (mean value:
72.2 ± 39.3 in H. pylori-negative patients versus 67.7 ±
28.4 in H. pylori-positive), (Table 3).
The pH-metric parameters, that is, reflux episodes,
pathological reflux episodes (refluxes with pH <4 that
last over five minutes) and extent of esophageal acid ex-
posure, were similar in both groups (Table 4).ording to the presence or absence of H. pylori infection
H. pylori-positive patients, n (%) Total patients, n (%)
85 (46.2) 184 (100)
32 (37.6) 73 (39.1)
53 (62.3) 111(51.6)
17 to 73 (50.1) 17 to 74 (49.72)







Reflux episodes 113.9 ± 147.8 135.1 ± 129 NS
Pathological reflux episodes 3.3 ± 6.7 2.4 ± 4.3 NS
Esophageal acid
exposure (minutes)
117 ± 195.2 109.3 ± 205.5 NS
DeMeester score 35.9 ± 56.7 33.3 ± 48.4 NS
NS, Not Significant
Table 2 Clinical parameters and symptoms score* of 184
patients with gastroesophageal reflux disease
Symptoms H. pylori-positive H. pylori-negative P value
Patients 85/184 99/184
Regurgitation (%) 36 (42.3%) 61 (61.6%) NS
(Score 0-4) (1.56 ± 0.81) (1.59 ± 0.11)
Dysphagia (%) 7 (8.2%) 21 (21.2%) NS
(Score 0-4) (1.86 ± 0.26) (1.57 ± 0.15)
Heartburn (%) 39 (45.9%) 61 (61.6%) NS
(Score 0-4) (1.82 ± 0.10) (1.90 ± 0.09)
Epigastric pain (%) 14 (16.5%) 17 (17.2%) NS
(Score 0-4) (1.50 ± 0.17) (1.47 ± 0.17)
Thoracic pain (%) 29 (34.1%) 45 (45.4%) NS
(Score 0-4) (1.34 ± 0.10) (1.89 ± 0.44)
Dyspepsia (%) 12 (14.1%) 17 (17.2%) NS
(Score 0-4) (1.75 ± 0.18) (1.71 ± 0.17)
Other symptoms (%) 14 (16.5%) 21 (21.2%) NS
*Data are given as mean ± standard error. Scores range from 0 (best) to 4
(worse). NS, Not Significant.
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on the DeMeester scale; 22 patients were H. pylori-posi-
tive (23.1%) and 73 were H. pylori-negative (76.8%). The
mean value of the DeMeester score was 35.9 ± 56.7 in
H. pylori-positive patients versus 33.3 ± 48 in H.
pylori-negative, and this difference was not significant.
In addition, to investigate the influence of the men-
tioned clinical, endoscopic and functional variables on
reflux esophagitis, a univariate analysis of clinical, endo-
scopic and functional parameters was performed, con-
sidering the presence of esophagitis as independent
variable. We observed that hiatal hernia (P = 0.01), LES
opening (P = 0.05), esophageal wave length (P = 0.01)
and pathological reflux number (P = 0.05) were signifi-
cantly related to the presence of esophagitis. However,
H. pylori infection was not significantly related to the
presence of reflux esophagitis.Table 3 Manometric data of 140 patients with
esophageal impairment motility
Parameters H. pylori-positive H. pylori-negative P value
Patients 33 107








67.7 ± 28,4 72.2 ± 39,3 NS
v.n. 33-91 (mmHg)
NS, Not Significant.Discussion
The incidence of H. pylori infection in patients with
GERD varies widely in literature from 30 to 90%, and is
approximately of 35% in most series [12]. This hetero-
geneity between the studies may be due to the geograph-
ical location of the studies due to the difference in the
prevalence of H. pylori in the Far East, North America
and Western Europe [8]. It was suggested that H. pylori
could contribute to GERD through different mecha-
nisms: the development of antral gastritis which in-
creases acid production, a decrease of LES pressure and
impairment of gastric filling [10]. Nevertheless, the de-
creasing prevalence of H. pylori infection and related
diseases (ulcer disease and gastric cancer) in Western
countries has been paralleled by an increased incidence
of gastroesophageal reflux and related complications.
These epidemiological data do not support a causative
role of H. pylori for reflux disease, but suggest a negative
association [11].
Esophageal H. pylori infection is uncommon in pa-
tients with Barrett’s IM, dysplasia, or adenocarcinoma,
and may be restricted to the non-intestinalized columnar
epithelium. Gastric H. pylori infection may have a pro-
tective effect for the development of Barrett’s esophagus
[13]; this data was also found in our study, although the
small sample size should be emphasized. Other authors
have even found a lower prevalence of H. pylori infec-
tion in patients with reflux symptoms and have sug-
gested a 'protective' role of H. pylori infection against
the development of esophageal diseases [14,15]. Smout
believed that pre-existing LES dysfunction and gastritis,
and susceptibility to reflux, increased by a latent reflux,
are probably causative factors contributing to esophageal
diseases, rather than H. pylori infection [14]. Another
possible explanation for the heterogeneous results re-
garding the relationship between GERD and H. pylori
may be related to the variable effect of H. pylori on gas-
tric acid.
According to Gisbert et al. [16], who found no influ-
ence of H. pylori infection either on pH-metric data or
on endoscopic findings, in our trial out of 184 GERD pa-
tients, 46% were H. pylori-infected while 54% were H.
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difference regarding presence and severity of reflux
esophagitis between patients with and without H. pylori
infection. Contrary to our study, most trials base the
correlation between H. pylori infection and GERD only on
endoscopic observations; the endoscopic pattern of GERD
patients is often normal, and 24-hour pH-monitoring re-
vealed a high diagnostic accuracy for GERD [17,18]. Actu-
ally, even if the role of acid secretion in esophageal lesions
is undeniable, it does not seem increased in GERD pa-
tients [19,20]. In the present study, we found no correl-
ation between H. pylori infection and pH-metric data, and
the mean value of the DeMeester score was similar in H.
pylori-positive and -negative patients as found by Oberg et
al. [21]. Further, the total time of acidification was similar
in both groups as outlined by Oberg et al. [21], who did
not find any correlation between H. pylori infection and
esophageal exposure to acid, detected by 24 hours pH-
metry, in patients with erosive esophagitis or Barrett's
esophagus. Schwizer et al. [22] studied 70 patients with
GERD treated with lansoprazole associated with clarithro-
mycin and amoxicillin in patients with H. pylori infection.
There was no difference in 24-hour pH values before and
after H. pylori eradication, suggesting that H. pylori eradi-
cation did not affect distal esophageal acid exposure.
In our study, we found an unusual prevalence of hiatal
hernia in contrast with some authors [23,24]. We are
not able to explain this data, however one theory is that
it may be due to the excessive attention with which this
condition was searched for. The incidence of patients
with hiatal hernia and no H. pylori infection was higher
than patients with H. pylori infection and hiatal hernia
(91 versus 31; P <0.0001). Moreover, according to a past
study [23] and this present one, the incidence of hiatal
hernia did not associate with RE (P <0.0001). We found
significant correlation between H. pylori infection and
hiatal hernia, considered by some authors as a support-
ing element of GERD, and significantly associated with
the development of esophagitis [23,24].
Virulent strains of H. pylori, including those with a
cytotoxin-associated gene named cagA+, have been re-
ported to be associated with significant gastric inflam-
mation [11]. H. pylori gastritis is accompanied by the
release of nitric oxide, cytokines and prostaglandins that
may impair afferent nerve function, reduce LES pressure
and damage esophageal mucosa [25,26]. However, in
contrast to other authors [27,28], in our trial LES pres-
sure was similar in patients with and without H. pylori
infection. Further, out of 184 GERD patients only 26%
had LES pressure <14 mmHg, and LES opening (P =
0.05) and esophageal wave length (P = 0.01) were signi-
ficantly related to esophagitis.
The relationship between H. pylori infection and gas-
tric adenocarcinoma is also controversial. Some authorssuggest an increased risk of gastric atrophy in H. pylori-
positive patients treated with long-term proton pump in-
hibitor therapy. In a small subset of H. pylori-infected
patients, chronic gastritis may lead to gastric atrophy
and intestinal metaplasia, a potential precursor for gas-
tric adenocarcinoma [29].
In a recent randomized controlled trial by Kuipers et al.
[30], none of the H. pylori-positive GERD patients treated
with anti-reflux surgery developed gastric atrophy, com-
pared to 31% of patients treated with proton pump inhibi-
tor therapy for an average of five years. Differently, in a
long-term trial of GERD patients treated for years with
omeprazole, there was an increase both in the severity of
corpus gastritis and in gastric atrophy in H. pylori-positive
patients [31]. Amongst the H. pylori-infected patients, atro-
phy was detected in 12% at baseline and 39% on follow-up.
Contrarily, it has been suggested that H. pylori cagA+
may potentially protect against complications of GERD,
such as Barrett's esophagus and dysplasia and adenocar-
cinoma [32,33]. The H. pylori infection in patients with
Barrett's esophagus has been reported in 12 to 60% cases
[34-37]. A recent meta-analysis presented at Digestive
Disease Week 2002 reported a negative association be-
tween the prevalence of H. pylori and cagA +H. pylori
and reflux disease, Barrett's esophagus and esophageal
adenocarcinoma [38].
Conclusions
The exact association between H. pylori and reflux disease
continues to be debated. Our clinical, endoscopic mano-
metric and pH-metric data show a significant role of H.
pylori infection neither in the development of GERD nor
in the pathogenesis of reflux esophagitis. However, there
are the works in the literature that analyze all the variables
we considered. Nevertheless, current data do not provide
sufficient evidence to define the relationship between H.
pylori and GERD. We are fully in agreement with Wu et
al. [19] in stating that a comparative study of H. pylori
gastritis patterns between GERD patients and non-reflux
controls is therefore mandatory.
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